Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Names New CFO as M&A Strategy Rolls Up Sleeves

SAN FRANCISCO, June 19 - Invitrogen has promoted C. Eric Winzer into the CFO position, the company said today.


Winzer, formerly vice president for finance, takes over from James Glynn, who will remain executive vice president and on the board of directors.


The shuffle is designed to give Glynn more time to focus on mergers and acquisitions, a "major strategy" of the company, an Invitrogen spokesperson told GenomeWeb.


Invitrogen has the cash to do it: At the end of the first quarter 2002, the company reported $694 million in cash and cash equivalents.


Winzer was CFO of Life Technologies prior to the company's acquisition by Invitrogen in 2000.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.